Recent Research and Developments have brought forward the pivotal role of radiotheranostics for cancer care. Whether you refer to them as Radiotheranostics, Theranostics, Theragnostics, Radioligand [...]
Dolgin, E. Drugmakers go nuclear, continuing push into radiopharmaceuticals. Nat Biotechnol 39, 647–649 (2021). Radiotheranostics Tsunami! Interesting recent read about the growing clinical and financial interest in radiopharmaceuticals [...]
Evaluate Vantage, Jacob Plieth, June 3, 2021 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase [...]
Urology Times Journal, Jason M. Broderick - April 15, 2021 The PSMA-targeted radiopharmaceutical 177Lu-PSMA-617 (LuPSMA) is rapidly advancing through the pipeline in metastatic castration-resistant prostate [...]
225Ac-PSMA RLT is an efficacious and safe treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Future randomized controlled trials are required to establish [...]
Available since 2015, the treatment of patients with metastatic castration-resistant prostate cancer (mCRPCC) with the beta-emitter Lutetium-177 has had several early-stage dosimetry studies published, demonstrated [...]
Looking back at 2020 accomplishments, fundraising campaign, meeting the newcomers Ambassadors, focusing on the latest developments in the Radiotheranostics field and meeting Tom, neuroendocrine cancer [...]
First clinical results for PSMA targeted alpha therapy using 225Ac-PSMA-I&T in advanced metastatic castration resistant prostate cancer patients: promising antitumor effect in advanced mCRPC even [...]
International Atomic Energy Agency (IAEA) activities on 67Cu, 186Re, 47Sc Theranostic radionuclides and Radiopharmaceuticals: Extraordinary results on the production, quality control and preclinical evaluation of [...]
The implementation of theranostic approaches to characterize and personalize patient management is beginning to be realized for prostate cancer patients. This review article summarized clinically [...]
Interesting interview with Pr. Michael Hofman about TheraP Trial Design Evaluating 177Lu‐PSMA‐617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration‐Resistant Prostate Cancer, where results are expected [...]
Targeted α-therapy with 225Ac-PSMA-617 although still preliminary, has demonstrated strong potential to significantly benefit advanced-stage prostate cancer patients. Dr. Machaba Michael Sathekge comments the initial [...]
Patient/public involvement and engagement (PPI/PE) incorporates and integrates individual’s perspectives in the planning and improvement of healthcare services and research: “No matter how complicated the [...]
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.